Dear Medtech: I’m Not Sick, So Why Do You Keep Calling Me a ‘Patient’?

Posted by Brian Chapman on May 17, 2019

Mick Jagger, The Rolling Stones’ 75-year-old lead singer, recently underwent a transcatheter aortic valve replacement procedure. A look at his Twitter feed shows a total of two tweets dedicated to this episode of care: First, he expressed his dismay at postponing the North American leg of his band’s tour and then, after a brief Twitter hiatus, he said that he’s feeling better and thanked the hospital staff. Do you think that the king of swagger wants to be considered a “patient” outside of this encounter? Not a chance.


>
Read More

What It Takes for Multinational Medtech Companies to Succeed in China

Posted by ZS Editors on April 9, 2019

With a population of 1.4 billion, China is a market that most medtech companies can’t afford to ignore. However, differences in population types (urban versus rural), the government’s role in healthcare expansion and a multi-tiered distribution system that is undergoing reform make navigating the Chinese market a challenge.


>
Read More

Value-Based Healthcare Is So 2015. Now Products Are the Talk of Medtech

Posted by Brian Chapman on March 20, 2019

For as long as I can remember, value-based healthcare has been the talk of the medtech industry, and for good reason: Who can argue with efforts to improve patient outcomes at a lower cost? With such virtuous and unassailable aims, it’s the irresistible force that dominated strategies in the last decade.


>
Read More

Thanks for the ‘Ones’ and ‘Zeros,’ Dr. Gottlieb

Posted by Brian Chapman on March 15, 2019

I admit, the title of this post is an attempt at a ham-fisted connection between the FDA’s impressive, forward-looking digital strategy under Commissioner Scott Gottlieb (as he wraps up his post following his March 5th resignation) and an overall reckoning from his tenure. I also must admit that my assessment has some shortcomings: I watch the FDA from a distance, avoid the political elements and focus only on the medtech industry (drug prices, generic approvals and vaping notwithstanding). Although Jeffrey Shuren, the director of the Center for Devices and Radiological Health, and others at the FDA probably should share credit for many of the positive accomplishments in medtech, the tenure of a leader should be judged by the organization’s accomplishments during that time. As Gottlieb prepares to move on from his role in public service, I’d like to share a few thoughts on the agency’s recent impact on the medtech industry.


>
Read More

The End of the ‘Features War’: The Changing Definition of Value in Medtech

Posted by Brian Chapman on June 8, 2017

This blog post also appears on The Advanced Medical Technology Association's Medtech Conference blog.

Flipping through the duty-free catalog on a recent flight, I was amazed that the luxury watches section spanned 38 pages and touted features like triple-polished sapphire crystals, 300-meter water resistance, rotating bezels and dual faces with multiple time zones. I nervously glanced at my own Garmin GPS running watch and its blocky digital time display.


>
Read More